Works by Xu, Rui-hua

Results: 149
    1
    2
    3
    4
    5
    6

    Standard: Human gastric organoids.

    Published in:
    Cell Regeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s13619-024-00218-6
    By:
    • Hong, Fan;
    • Tan, Ronghui;
    • Wang, Ting;
    • Zhong, Nanshan;
    • Zhao, Hongling;
    • Xu, Rui-hua;
    • Shen, Lin;
    • Liu, Yingbin;
    • Yao, Xuebiao;
    • Xiang, Dongxi;
    • Hui, Lijian;
    • Xiong, Jianping;
    • Gao, Dong;
    • Zhao, Bing;
    • Miao, Zhifeng;
    • Hao, Jie;
    • Li, Yong;
    • Hu, Shijun;
    • Fu, Boqiang;
    • Hua, Guoqiang
    Publication type:
    Article
    7

    Standard: Human gastric cancer organoids.

    Published in:
    Cell Regeneration, 2024, v. 13, n. 1, p. 1, doi. 10.1186/s13619-024-00217-7
    By:
    • Tan, Ronghui;
    • Hong, Fan;
    • Wang, Ting;
    • Zhong, Nanshan;
    • Zhao, Hongling;
    • Xu, Rui-hua;
    • Shen, Lin;
    • Liu, Yingbin;
    • Yao, Xuebiao;
    • Xiang, Dongxi;
    • Gao, Dong;
    • Xiong, Jianping;
    • Hui, Lijian;
    • Zhao, Bing;
    • Miao, Zhifeng;
    • Hao, Jie;
    • Li, Yong;
    • Hu, Shijun;
    • Fu, Boqiang;
    • Hua, Guoqiang
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27

    Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer.

    Published in:
    Cancer Medicine, 2020, v. 9, n. 1, p. 151, doi. 10.1002/cam4.2693
    By:
    • Wang, De‐shen;
    • Wang, Zhi‐qiang;
    • Chen, Gong;
    • Peng, Jie‐wen;
    • Wang, Wei;
    • Deng, Yan‐hong;
    • Wang, Feng‐hua;
    • Zhang, Jian‐wei;
    • Liang, Han‐lin;
    • Feng, Fen;
    • Xie, Chuan‐bo;
    • Ren, Chao;
    • Jin, Ying;
    • Shi, Si‐mei;
    • Fan, Wen‐hua;
    • Lu, Zhen‐hai;
    • Ding, Pei‐rong;
    • Wang, Feng;
    • Xu, Rui‐hua;
    • Li, Yu‐hong
    Publication type:
    Article
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39

    First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305.

    Published in:
    Advances in Therapy, 2025, v. 42, n. 5, p. 2248, doi. 10.1007/s12325-025-03133-7
    By:
    • Moehler, Markus;
    • Oh, Do-Youn;
    • Kato, Ken;
    • Arkenau, Tobias;
    • Tabernero, Josep;
    • Lee, Keun-Wook;
    • Rha, Sun Young;
    • Hirano, Hidekazu;
    • Spigel, David;
    • Yamaguchi, Kensei;
    • Wyrwicz, Lucjan;
    • Disel, Umut;
    • Pazo-Cid, Roberto A.;
    • Fornaro, Lorenzo;
    • Xu, Yaling;
    • Sheng, Tao;
    • Yang, Silu;
    • Kadva, Alysha;
    • Cruz-Correa, Marcia;
    • Xu, Rui-Hua
    Publication type:
    Article
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Expert opinions on immunotherapy for patients with colorectal cancer.

    Published in:
    Cancer Communications, 2020, v. 40, n. 10, p. 467, doi. 10.1002/cac2.12095
    By:
    • Wang, Feng;
    • Wang, Zi‐Xian;
    • Chen, Gong;
    • Luo, Hui‐Yan;
    • Zhang, Dong‐Sheng;
    • Qiu, Miao‐Zhen;
    • Wang, De‐Shen;
    • Pan, Zhi‐Zhong;
    • Shen, Lin;
    • Li, Jin;
    • Zhang, Su‐Zhan;
    • Xu, Rui‐Hua
    Publication type:
    Article
    49
    50